Industry news
- Industry news
- Intellectual Property
News of the day
SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS
CALGARY, Sept. 1, 2010 - SemBioSys Genetics Inc. (TSX:SBS) today announced that the United States Patent and Trade Mark Office has granted the Company U.S. patent 7,786,352 entitled "Methods for the Production of Apolipoproteins in Transgenic Plants". The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into... moreStemCells, Inc's Technology Used to Create First Genetically Engineered Rat Derived from Rat Embryonic Stem Cells
PALO ALTO, Calif., August 31, 2010 - StemCells, Inc. (NASDAQ: STEM) announced today that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the... moreMarina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
BOTHELL, WA, Aug 30, 2010--Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company's proprietary SMARTICLES(R) technology, for delivery of siRNAs and other compounds with therapeutic application. moreIndustry news search
Most Viewed
SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS
Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
Recent news
To keep up to date with news from this category use our 
Sequella and University of Maryland Restate Exclusive License for Jointly-owned Event Marker System Technology
Rockville, MD - August 30, 2010- Sequella, Inc., a clinical-stage company focused on commercialization of novel drugs for life-threatening infectious diseases, announced today the restatement of its exclusive...
Ranier Technology announces the European Patent Grant on its Precision Polyurethane Manufacturing (PPM) Technology
July 15, 2010--Cambridge, UK based Ranier Technology announced that they have received the grant of a European Patent for its Precision Polyurethane Manufacturing (PPM) materials manufacturing technology.
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us